R
Radleigh G. Santos
Researcher at Torrey Pines Institute for Molecular Studies
Publications - 45
Citations - 1436
Radleigh G. Santos is an academic researcher from Torrey Pines Institute for Molecular Studies. The author has contributed to research in topics: T cell & Antigen. The author has an hindex of 17, co-authored 42 publications receiving 1118 citations. Previous affiliations of Radleigh G. Santos include Nova Southeastern University.
Papers
More filters
Journal ArticleDOI
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.
Ivan Jelcic,Faiez Al Nimer,Faiez Al Nimer,Jian Wang,Verena Lentsch,Raquel Planas,Ilijas Jelcic,Aleksandar Madjovski,Sabrina Ruhrmann,Wolfgang Faigle,Katrin Frauenknecht,Clemencia Pinilla,Radleigh G. Santos,Christian Hammer,Christian Hammer,Yanneth Ortiz,Lennart Opitz,Hans Grönlund,Gerhard Rogler,Onur Boyman,Richard Reynolds,Andreas Lutterotti,Mohsen Khademi,Tomas Olsson,Frederik Piehl,Mireia Sospedra,Roland Martin +26 more
TL;DR: It is demonstrated that self-reactivity, defined as “autoproliferation” of peripheral Th1 cells, is elevated in patients carrying the HLA-DR15 haplotype, and RASGRP2 is identified as target autoantigen that is expressed in the brain and B cells.
Journal ArticleDOI
Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate.
Franck Madoux,Daniela Dreymüller,Jean-Phillipe Pettiloud,Radleigh G. Santos,Christoph Becker-Pauly,Andreas Ludwig,Gregg B. Fields,Thomas D. Bannister,Timothy P. Spicer,Mare Cudic,Louis Scampavia,Dmitriy Minond,Dmitriy Minond +12 more
TL;DR: Results of the present and prior studies strongly suggest that glycosylated substrate are applicable as screening agents for discovery of selective ADAM probes and therapeutics.
Journal ArticleDOI
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.
Patrick Y. Wen,David A. Reardon,Terri S. Armstrong,Surasak Phuphanich,Robert Aiken,Joseph Landolfi,William T. Curry,Jay-Jiguang Zhu,Michael Glantz,David M. Peereboom,James M. Markert,Renato V. LaRocca,Donald M. O'Rourke,Karen Fink,Lyndon Kim,Michael L. Gruber,Glenn J. Lesser,Edward Pan,Santosh Kesari,Alona Muzikansky,Clemencia Pinilla,Radleigh G. Santos,John S. Yu +22 more
TL;DR: HLA-A2 patients achieved a meaningful therapeutic benefit with ICT-107, in both the MGMT methylated and unmethylated prespecified subgroups, whereas only Hla-A1 methylated patients had an OS benefit.
Journal ArticleDOI
Structure–activity relationships of benzimidazole derivatives as antiparasitic agents: Dual activity-difference (DAD) maps
Jaime Pérez-Villanueva,Radleigh G. Santos,Alicia Hernández-Campos,Marc A. Giulianotti,Rafael Castillo,José L. Medina-Franco +5 more
TL;DR: A systematic characterization of the structure–activity relationships (SAR) of a comprehensive set of benzimidazole derivatives tested against Trichomonas vaginalis and Giardia intestinalis is reported.
Journal ArticleDOI
Combinatorial Libraries As a Tool for the Discovery of Novel, Broad-Spectrum Antibacterial Agents Targeting the ESKAPE Pathogens.
Renee Fleeman,Travis LaVoi,Radleigh G. Santos,Angela Morales,Adel Nefzi,Gregory S. Welmaker,José L. Medina-Franco,Marc A. Giulianotti,Richard A. Houghten,Lindsey N. Shaw +9 more
TL;DR: This study used a scaffold-ranking library to screen 37 different libraries for antibacterial activity against the ESKAPE pathogens and identified a bis-cyclic guanidine library that displayed strong antib bacterial activity.